tetano
Editor, Senior Moderator
Vaccine
. 2022 Jan 11;S0264-410X(21)01669-8.
doi: 10.1016/j.vaccine.2021.12.061. Online ahead of print.
Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly
Sakiko Shimizu[SUP] 1 [/SUP], Ryo Tanaka[SUP] 1 [/SUP], Eriko Itoh[SUP] 1 [/SUP], Minami Maekawa-Matsuura[SUP] 1 [/SUP], Yoichiro Iwase[SUP] 2 [/SUP]
Affiliations
Abstract
Under the pandemic situation, there is an urgent need to produce and acquire sufficient quantities of prophylactic vaccines. It becomes important to devise a way to achieve reliable immunity with lower doses to distribute limited supplies of vaccines to maximum number of people very quickly. Intradermal (ID) vaccination is one such method to increase the effectiveness of vaccines. However, this method has not been widely used in general clinical practice because it is technically difficult to inject vaccines precisely into the ID tissue. Therefore, new ID delivery systems that allow reliable ID administration are under development. In this paper, we summarize its design and present the results of performance and usability testing for the Immucise™ Intradermal Injection System (Immucise™). This study showed that Immucise™ can reduce dead volume and inject drugs precisely into the ID tissues of subjects from infants to the elderly and can be used correctly and safely by healthcare professionals. This randomized controlled trial compared ID administration with Immucise™ and standard subcutaneous (SC) administration of seasonal influenza vaccine by analyzing the efficacy of the vaccine in the elderly group at 90 days and 180 days after administration. It was found that the vaccine for the ID group was as effective or more effective than that for the SC group up to 180 days later. It was also found that the geometric mean titer values, especially for B strains, were higher in the two-dose ID group than in the two-dose SC group. These findings suggest that Immucise™ is one of the best devices to distribute a small amount of vaccine quickly and widely to a larger number of people with little loss of vaccine during a pandemic.
Keywords: Drug delivery device; Influenza; Intradermal injection; Vaccine.
. 2022 Jan 11;S0264-410X(21)01669-8.
doi: 10.1016/j.vaccine.2021.12.061. Online ahead of print.
Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly
Sakiko Shimizu[SUP] 1 [/SUP], Ryo Tanaka[SUP] 1 [/SUP], Eriko Itoh[SUP] 1 [/SUP], Minami Maekawa-Matsuura[SUP] 1 [/SUP], Yoichiro Iwase[SUP] 2 [/SUP]
Affiliations
- PMID: 35031147
- DOI: 10.1016/j.vaccine.2021.12.061
Abstract
Under the pandemic situation, there is an urgent need to produce and acquire sufficient quantities of prophylactic vaccines. It becomes important to devise a way to achieve reliable immunity with lower doses to distribute limited supplies of vaccines to maximum number of people very quickly. Intradermal (ID) vaccination is one such method to increase the effectiveness of vaccines. However, this method has not been widely used in general clinical practice because it is technically difficult to inject vaccines precisely into the ID tissue. Therefore, new ID delivery systems that allow reliable ID administration are under development. In this paper, we summarize its design and present the results of performance and usability testing for the Immucise™ Intradermal Injection System (Immucise™). This study showed that Immucise™ can reduce dead volume and inject drugs precisely into the ID tissues of subjects from infants to the elderly and can be used correctly and safely by healthcare professionals. This randomized controlled trial compared ID administration with Immucise™ and standard subcutaneous (SC) administration of seasonal influenza vaccine by analyzing the efficacy of the vaccine in the elderly group at 90 days and 180 days after administration. It was found that the vaccine for the ID group was as effective or more effective than that for the SC group up to 180 days later. It was also found that the geometric mean titer values, especially for B strains, were higher in the two-dose ID group than in the two-dose SC group. These findings suggest that Immucise™ is one of the best devices to distribute a small amount of vaccine quickly and widely to a larger number of people with little loss of vaccine during a pandemic.
Keywords: Drug delivery device; Influenza; Intradermal injection; Vaccine.